Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease

Stock Information for Annovis Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Annovis Bio Inc.

Annovis Bio Appoints Hui Liu as Director of Biostatistics
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
Annovis to Attend AD/PD(TM) 2025 with Extensive Scientific Program
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
Annovis to Host Patients' Live Forum on February 27, 2025
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.